What Is a Microdose of Tirzepatide? The Specific Numbers Patients Are Actually Using

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 10 sources cited

Key Takeaways

• Patient-reported microdoses of tirzepatide range from 0.5 mg to 2 mg weekly, with 1 mg and 1.25 mg most commonly cited
• The FDA-approved starting dose is 2.5 mg weekly. Anything below is off-label and outside the approved label.
• Brand pens (Mounjaro, Zepbound) are not manufactured at sub-2.5 mg doses. Microdoses are typically prepared by 503A compounding pharmacies.
• Patient communities use insulin syringes drawn to specific unit marks based on the concentration of the compounded preparation
• Sub-therapeutic doses produce sub-therapeutic effects on average; controlled trial data does not exist for doses below 2.5 mg

Direct answer

A microdose of tirzepatide is typically 0.5 mg to 2 mg weekly, below the FDA-approved 2.5 mg starting dose. The most commonly cited microdoses in patient communities are 1 mg and 1.25 mg weekly. Microdoses are not standardized and reflect patient-driven practice rather than clinically validated regimens. They are typically obtained through compounded tirzepatide at custom concentrations.

Table of contents

1. The microdose range patients actually use
2. Comparison to FDA-approved doses
3. Why 1 mg is the most common starting point
4. The 0.5 mg threshold and what it reportedly produces
5. How patients measure microdoses with insulin syringes
6. Concentration matters: doing the math
7. The pulsed-dosing variant
8. Side effects at sub-therapeutic doses
9. Microdose as maintenance versus microdose as primary treatment
10. When microdosing makes clinical sense and when it does not
11. The contrary view: maybe 2.5 mg should be the minimum
12. FAQ
13. Sources

The microdose range patients actually use

Across Reddit, patient forums, and clinical observation, microdoses fall into a recognizable range:

Dose	Patient-reported usage	Common purpose
0.25 to 0.5 mg weekly	Uncommon; exploratory	Extreme tolerability or maintenance
0.5 to 1 mg weekly	Used by patients with severe side effects at 2.5 mg	Side-effect minimization
1 mg weekly	Common starting microdose	Entry point for new microdosers
1.25 mg weekly	Half of FDA starting dose	Halfway position for sensitive patients
1.5 to 2 mg weekly	Approaching FDA threshold	Late microdose before standard dosing

None of these doses are formally validated. They reflect what patients are doing in practice, not what controlled trials have evaluated.

Comparison to FDA-approved doses

The FDA-approved dose schedule for tirzepatide:

• 2.5 mg weekly: Starting dose, weeks 1 to 4. Not considered a therapeutic dose for weight loss.
• 5 mg weekly: First therapeutic dose. SURMOUNT-1 showed approximately 15% weight loss at 72 weeks at this dose.
• 7.5 mg weekly: Optional intermediate dose.
• 10 mg weekly: Common maintenance dose. Approximately 19.5% weight loss at 72 weeks per SURMOUNT-1.
• 12.5 mg weekly: Optional higher dose.
• 15 mg weekly: Maximum approved dose. Approximately 22.5% weight loss at 72 weeks per SURMOUNT-1.

Microdoses (0.5 to 2 mg weekly) sit below all of these. The FDA's choice of 2.5 mg as the starting dose reflects a clinical judgment about tolerability and minimum useful exposure for adaptation purposes, not about therapeutic threshold.

Why 1 mg is the most common starting point

The 1 mg weekly dose is frequently cited in patient communities as a default microdose. Several reasons:

• Round number, easy to remember
• Common concentration in compounded tirzepatide (10 mg/mL means 1 mg = 0.1 mL = 10 units)
• Roughly 40% of the FDA starting dose, perceived as a meaningful step down
• Anecdotally reported to produce noticeable appetite suppression in many patients
• Generally well-tolerated with minimal side effects

None of these are formal scientific justifications. The 1 mg figure has emerged through patient consensus rather than clinical guidance.

The 0.5 mg threshold and what it reportedly produces

At 0.5 mg weekly, patient reports are mixed:

• Some patients describe noticeable appetite reduction
• Others describe no detectable effect
• Side effects at this dose are uncommon
• Weight loss outcomes are typically modest (1 to 2% over months) when reported at all

The 0.5 mg level appears to be near the lower threshold where pharmacological effects may manifest. Below 0.5 mg, patient reports of any effect become rare. Whether this represents a true pharmacological threshold or a perception threshold is unclear without controlled studies.

How patients measure microdoses with insulin syringes

Compounded tirzepatide is typically supplied in multi-dose vials at specific concentrations. Patients draw doses using insulin syringes, which are calibrated in units (1 unit = 0.01 mL of 100-unit insulin).

For tirzepatide, the unit markings on an insulin syringe correspond to milliliters drawn, not to milligrams of tirzepatide. The actual mg dose depends on the concentration of the compounded preparation.

Compounded concentration	1 mg dose = how many units	2.5 mg dose = how many units
5 mg/mL	20 units (0.2 mL)	50 units (0.5 mL)
10 mg/mL	10 units (0.1 mL)	25 units (0.25 mL)
20 mg/mL	5 units (0.05 mL)	12.5 units (0.125 mL)

Patients must know the concentration of their specific preparation to dose correctly. Misreading the concentration can lead to substantial dose errors. The compounding pharmacy should provide clear dose-to-unit conversions on the label or accompanying instructions.

Concentration matters: doing the math

A worked example for clarity:

If your compounded tirzepatide is supplied at 10 mg/mL, and you want a 1.25 mg dose:

1. 1.25 mg ÷ 10 mg/mL = 0.125 mL
2. 0.125 mL × 100 (insulin syringe unit conversion) = 12.5 units
3. Draw to the 12 or 13 unit mark on an insulin syringe

Patients new to compounded medication or microdosing should confirm the math with the dispensing pharmacy. Errors are easy to make and consequential. A pharmacist can write the unit-equivalent on the label as a check.

The pulsed-dosing variant

Some microdose protocols use pulsed schedules rather than steady weekly dosing:

• 2.5 mg every 10 to 14 days (less frequent than weekly)
• 1 mg twice weekly (two smaller doses per week)
• Skip-week protocols (5 mg every other week)

The rationale: keeping average weekly exposure low while occasionally reaching higher peak concentrations.

The evidence base for pulsed schedules is even thinner than for steady microdosing. Tirzepatide's half-life of about 5 days produces relatively stable plasma levels with weekly dosing; longer intervals create more variability. Whether this variability is helpful or harmful is unstudied.

Side effects at sub-therapeutic doses

Sub-therapeutic doses generally produce fewer side effects than therapeutic doses. Typical patient reports at microdoses:

• Nausea: uncommon and usually mild when present
• Vomiting: rare
• Sulfur burps: uncommon
• Constipation: occasional, usually mild
• Injection-site reactions: similar rate to standard dosing
• Fatigue: occasional

This reduced side-effect burden is a major reason patients choose microdoses. The tradeoff is reduced weight-loss effect. Patients should expect more modest results at microdoses, even if individual responses vary.

Microdose as maintenance versus microdose as primary treatment

Two distinct use cases that often get conflated:

Microdose as primary treatment. Patient starts at a microdose and continues at that level indefinitely without ever moving to therapeutic doses. Goal may be modest weight loss with minimal side effects, or metabolic effects without significant weight change. Evidence base is essentially zero.

Microdose as maintenance. Patient lost their target weight on therapeutic doses (typically 10 to 15 mg) and tapers down to a microdose to maintain weight loss with reduced side effects. Evidence base is also thin; the SURMOUNT-4 trial showed substantial regain after discontinuation, but optimal maintenance dosing was not specifically studied.

These are different clinical situations with different risk-benefit profiles. Discussion with a prescriber should distinguish which scenario applies.

When microdosing makes clinical sense and when it does not

Microdosing may make sense when:

• Patient has severe intolerance to 2.5 mg starting dose
• Patient is in long-term maintenance after reaching goal weight
• Patient is small-framed or sensitive to medications generally
• Cost or supply constraints prevent therapeutic dosing
• Patient prefers modest gradual change over standard rapid loss

Microdosing likely does not make sense when:

• Patient has not yet tried tolerability strategies at standard doses (slow titration, anti-nausea support)
• Patient has substantial weight to lose and limited timeline
• Patient is using microdoses without prescriber involvement
• Patient confuses microdose with a starting dose intended for titration toward therapeutic levels
• Patient is paying for compounded medication while denying themselves the clinically validated benefit of standard dosing

The contrary view: maybe 2.5 mg should be the minimum

The case against microdosing as a routine practice:

• Controlled trial evidence shows efficacy at 5 mg and above; sub-therapeutic doses extrapolate beyond available data
• Most patient reports of microdose efficacy include lifestyle changes and placebo effects that confound attribution to the medication
• Resources spent on compounded microdoses might be better spent on standard therapeutic doses with appropriate tolerability support
• "Microdose" framing imports a wellness-culture aesthetic onto a serious clinical medication, potentially trivializing its appropriate use

This view has merit. Microdosing is not automatically wrong, but it should be a considered choice rather than a default. Standard dosing exists for evidence-based reasons, and choosing to deviate requires acknowledging the evidence gap.

FAQ

What is the typical microdose of tirzepatide? 0.5 to 2 mg weekly, with 1 mg and 1.25 mg most common.

Is 0.5 mg of tirzepatide effective? Patient reports vary. No controlled trial evidence at this dose.

How does a microdose compare to the FDA starting dose? Microdoses are below the 2.5 mg starting dose. Both are sub-therapeutic; the 2.5 mg dose is intended for titration toward therapeutic levels.

Why is there no microdose strength of brand Mounjaro? Eli Lilly's pen strengths start at 2.5 mg. Microdoses come from compounded preparations.

How do patients measure microdoses? Insulin syringes drawn to specific unit marks based on the concentration of the compounded preparation.

Is a microdose the same as a maintenance dose? Not necessarily. Maintenance doses can be therapeutic; microdoses are by definition sub-therapeutic. Some patients use microdoses for maintenance, but the concepts are distinct.

Can a microdose still cause side effects? Yes, although less commonly and less severely than standard doses.

What is the lowest tirzepatide dose patients use? Reported doses as low as 0.25 mg weekly exist but are uncommon. The 0.5 mg level is near the lower threshold of typical microdosing.

Is microdosing safe? Lower doses generally produce fewer side effects, but unique safety concerns at sub-therapeutic doses are unstudied.

Will microdosing produce SURMOUNT-1 weight loss results? No. SURMOUNT-1 tested 5, 10, and 15 mg. Microdose outcomes are not directly comparable.

Should I tell my doctor I am microdosing? Yes. Honest communication helps your prescriber make informed decisions about your care and identify any concerns.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide. New England Journal of Medicine. 2021.
3. Aronne LJ et al. Continued Treatment With Tirzepatide (SURMOUNT-4). JAMA. 2024.
4. Eli Lilly. Mounjaro (tirzepatide) Prescribing Information. 2024.
5. Eli Lilly. Zepbound (tirzepatide) Prescribing Information. 2024.
6. FDA. Statement on Compounded GLP-1 Medications. 2023.
7. USP <797>. Pharmaceutical Compounding Sterile Preparations. 2023.
8. Drucker DJ. Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism. 2018.
9. National Association of Boards of Pharmacy. 503A Compounding Standards. 2023.
10. Davies MJ et al. GLP-1 Receptor Agonists in Clinical Practice. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients to licensed prescribers and U.S. pharmacies. Microdosing decisions, including specific dose selection and titration, should be made in consultation with a licensed prescriber familiar with the patient's clinical situation.

Compounded Medication Notice. Compounded tirzepatide is prepared by 503A pharmacies under individual prescriptions. It is not FDA-approved and is not interchangeable with brand-name Mounjaro or Zepbound. Sub-therapeutic dosing is off-label and not clinically validated by controlled trials.

Results Disclaimer. Patient-reported outcomes at sub-therapeutic doses are anecdotal. Individual responses vary substantially, and population averages from SURMOUNT trials applied to therapeutic doses (5 to 15 mg) do not directly translate to microdoses.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly.